Last update 02 Feb 2026

SENL-103

Overview

Basic Info

Drug Type
Autologous CAR-T
Synonyms
S 103, S-103(Hebei Senlangbio Biotechnology ), S103
+ [2]
Target
BCMA
Action
modulators
Mechanism
BCMA modulators(B-cell maturation protein modulators), Immunologic cytotoxicity, T lymphocyte replacements
Therapeutic Areas
NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases+ [3]
Active Indication
Multiple MyelomaMyasthenia GravisImmunoglobulin Light-Chain Amyloidosis+ [2]
Inactive Indication
Systemic Lupus Erythematosus
Originator Organization
Hebei Senlangbio Biotechnology Co., Ltd.Hebei Senlangbio Biotechnology Co., Ltd.
Active Organization
Hebei Senlangbio Biotechnology Co., Ltd.Hebei Senlangbio Biotechnology Co., Ltd.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Related

4
Clinical Trials associated with SENL-103
ChiCTR2500112137
/ Not yet recruitingPhase 1IIT
An open-label, single-arm Phase I clinical study of SENL103 autologous T-cell injection (S103) for the treatment of refractory generalized myasthenia gravis
NCT06067581
/ Unknown statusEarly Phase 1
Clinical Study on the Safety and Efficacy of SENL103 Autologous T Cell Injection in the Treatment of Recurrent or Refractory Plasma Cell Blood Tumors
CTR20253934
/ Not yet recruitingPhase 1
SENL103自体T细胞注射液（S103）治疗难治性全身型重症肌无力的开放、单臂的I期临床研究
[Translation] An open, single-arm Phase I clinical study of SENL103 autologous T cell injection (S103) in the treatment of refractory generalized myasthenia gravis
100 Clinical Results associated with SENL-103
Login to view more data
100 Translational Medicine associated with SENL-103
Login to view more data
100 Patents (Medical) associated with SENL-103
Login to view more data
100 Deals associated with SENL-103
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Multiple MyelomaPhase 2
China
Hebei Senlangbio Biotechnology Co., Ltd.Hebei Senlangbio Biotechnology Co., Ltd.
12 Dec 2025
Myasthenia GravisPhase 1
China
Hebei Senlangbio Biotechnology Co., Ltd.Hebei Senlangbio Biotechnology Co., Ltd.
16 Oct 2025
Systemic Lupus ErythematosusClinical
China
Hebei Senlangbio Biotechnology Co., Ltd.Hebei Senlangbio Biotechnology Co., Ltd.
-
Immunoglobulin Light-Chain AmyloidosisIND Approval
China
Hebei Senlangbio Biotechnology Co., Ltd.Hebei Senlangbio Biotechnology Co., Ltd.
02 Feb 2026
Refractory Multiple MyelomaIND Approval
China
Hebei Senlangbio Biotechnology Co., Ltd.Hebei Senlangbio Biotechnology Co., Ltd.
19 Mar 2025
Relapse multiple myelomaIND Approval
China
Hebei Senlangbio Biotechnology Co., Ltd.Hebei Senlangbio Biotechnology Co., Ltd.
19 Mar 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free